AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
−0.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 219.1M | 236.2M | 160.2M | 194.6M | 292.5M |
| Cost of Revenue | 45.0M | 39.5M | 63.2M | 74.1M | 22.5M |
| Gross Profit | 174.1M | 196.7M | 97.0M | 120.5M | 270.0M |
| Operating Expenses | |||||
| R&D Expense | 70.1M | 62.4M | 37.7M | 63.1M | 166.0M |
| SG&A Expense | 114.7M | 107.5M | 106.5M | 100.2M | 138.6M |
| General & Admin Expense | — | — | — | — | 131.9M |
| Selling & Marketing Expense | — | — | — | 100.2M | 6.7M |
| Other Expenses | 4.4M | 3.4M | 3.3M | 3.4M | 46.2M |
| Total Operating Expenses | 189.2M | 173.2M | 147.5M | 166.7M | 350.8M |
| Cost and Expenses | 234.2M | 212.7M | 210.7M | 240.9M | 373.3M |
| Operating Income (EBIT) | (15.1M) | 23.5M | (50.5M) | (46.3M) | (80.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 8.0M | 24.2M | 18.2M | 6.0M | 15.7M |
| Net Interest Income | (8.0M) | (24.2M) | (18.2M) | (6.0M) | (15.7M) |
| Other Non-Op Income/Expense | (12.7M) | (27.2M) | (18.9M) | (5.7M) | (13.4M) |
| Non-Operating Income (excl Interest) | 4.8M | 3.0M | 753.0K | (363.0K) | (46.1M) |
| EBT (Pre-Tax Income) | (27.8M) | (3.7M) | (69.4M) | (51.9M) | (94.2M) |
| Income Tax Expense | 1.8M | 1.6M | — | — | — |
| Bottom Line | |||||
| Net Income | (29.7M) | (5.3M) | (69.4M) | (51.9M) | (94.2M) |
| Earnings from Cont. Ops | (29.7M) | (5.3M) | (69.4M) | (51.9M) | (94.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (29.7M) | (5.3M) | (69.4M) | (51.9M) | (94.2M) |
| Per Share | |||||
| Basic EPS | ($0.11) | ($0.02) | ($0.33) | ($0.28) | ($0.58) |
| Diluted EPS | ($0.11) | ($0.02) | ($0.33) | ($0.28) | ($0.58) |
| Revenue Per Share | $0.81 | $0.92 | $0.76 | $1.04 | $1.60 |
| Shares | |||||
| Basic Shares Outstanding | 269.6M | 257.2M | 210.9M | 187.5M | 182.8M |
| Diluted Shares Outstanding | 269.6M | 257.2M | 210.9M | 187.5M | 182.8M |
| Profitability Metrics | |||||
| EBITDA | (18.0M) | 21.7M | (13.7M) | (8.3M) | 3.1M |
| D&A | 1.9M | 1.3M | 37.5M | 37.6M | 37.7M |
| EBIT | (19.9M) | 20.5M | (51.2M) | (45.9M) | (34.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026